<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="editorial" xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">World J Psychiatry</journal-id>
<journal-id journal-id-type="publisher-id">WJP</journal-id>
<journal-title-group>
<journal-title>World Journal of Psychiatry</journal-title>
</journal-title-group>
<issn pub-type="ppub">2220-3206</issn>
<issn pub-type="epub">2220-3206</issn>
<publisher>
<publisher-name>Baishideng Publishing Group Inc</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26425441</article-id>
<article-id pub-id-type="pmc">4582303</article-id>
<article-id pub-id-type="other">jWJP.v5.i3.pg260</article-id>
<article-id pub-id-type="doi">10.5498/wjp.v5.i3.260</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Frontier</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Role of presynaptic phosphoprotein synapsin II in schizophrenia</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Molinaro</surname>
<given-names>Luke</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hui</surname>
<given-names>Patricia</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tan</surname>
<given-names>Mattea</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mishra</surname>
<given-names>Ram K</given-names>
</name>
</contrib>
<aff>Luke Molinaro, Patricia Hui, Mattea Tan, Ram K Mishra, Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario L8N 3Z5, Canada</aff>
</contrib-group>
<author-notes>
<fn>
<p>Author contributions: All authors contributed to this manuscript.</p>
<p>Correspondence to: Dr. Ram K Mishra, Department of Psychiatry and Behavioural Neurosciences, McMaster University, 1200 Main Street West, Hamilton, Ontario L8N 3Z5, Canada. <email>mishrar@mcmaster.ca</email></p>
<p>Telephone: +1-905-5259140-22396 Fax: +1-905-5228804</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<day>22</day>
<month>9</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="epub">
<day>22</day>
<month>9</month>
<year>2015</year>
</pub-date>
<volume>5</volume>
<issue>3</issue>
<fpage>260</fpage>
<lpage>272</lpage>
<history>
<date date-type="received">
<day>5</day>
<month>2</month>
<year>2015</year>
</date>
<date date-type="rev-recd">
<day>26</day>
<month>5</month>
<year>2015</year>
</date>
<date date-type="accepted">
<day>9</day>
<month>6</month>
<year>2015</year>
</date>
</history>
<permissions>
<copyright-statement>©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.</copyright-statement>
<copyright-year>2015</copyright-year>
</permissions>
<abstract>
<p>Synapsin II is a member of the neuronal phosphoprotein family. These phosphoproteins are evolutionarily conserved across many organisms and are important in a variety of synaptic functions, including synaptogenesis and the regulation of neurotransmitter release. A number of genome-wide scans, meta-analyses, and genetic susceptibility studies have implicated the <italic>synapsin</italic> II gene (<italic>3p25</italic>) in the etiology of schizophrenia (SZ) and other psychiatric disorders. Further studies have found a reduction of synapsin II mRNA and protein in the prefrontal cortex in post-mortem samples from schizophrenic patients. Disruptions in the expression of this gene may cause synaptic dysfunction, which can result in neurotransmitter imbalances, likely contributing to the pathogenesis of SZ. SZ is a costly, debilitating psychiatric illness affecting approximately 1.1% of the world’s population, amounting to 51 million people today. The disorder is characterized by positive (hallucinations, paranoia), negative (social withdrawal, lack of motivation), and cognitive (memory impairments, attention deficits) symptoms. This review provides a comprehensive summary of the structure, function, and involvement of the synapsin family, specifically synapsin II, in the pathophysiology of SZ and possible target for therapeutic intervention/implications.</p>
</abstract>
<kwd-group>
<kwd>Synapsin II</kwd>
<kwd>Schizophrenia</kwd>
<kwd>Dopamine</kwd>
<kwd>Glutamate</kwd>
<kwd>Neuropsychiatry</kwd>
<kwd>Antipsychotic drugs</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>